Short Interest in Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) Decreases By 89.2%

Neuren Pharmaceuticals Limited (OTCMKTS:NURPF) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totaling 16,560 shares, a drop of 89.2% from the July 15th total of 152,860 shares. Based on an average daily trading volume, of 2 shares, the short-interest ratio is presently 8,280.0 days.

Neuren Pharmaceuticals Stock Up 6.2%

NURPF stock opened at C$17.00 on Wednesday. The stock’s 50 day simple moving average is C$11.82 and its 200 day simple moving average is C$10.10. Neuren Pharmaceuticals has a fifty-two week low of C$7.70 and a fifty-two week high of C$17.25.

Neuren Pharmaceuticals Company Profile

Neuren Pharmaceuticals (OTCMKTS:NURPF) is an Australian-based clinical-stage biopharmaceutical company focused on developing innovative peptide-based therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders. The company’s research efforts center on addressing unmet medical needs in conditions such as Rett syndrome, Fragile X syndrome and Angelman syndrome. Neuren is publicly traded on the Australian Securities Exchange and maintains an over-the-counter listing in the United States, reflecting its commitment to global capital markets and investor engagement.

The company’s lead candidate, trofinetide (NNZ-2566), is a synthetic analogue of a naturally occurring peptide that has been evaluated in late-stage clinical trials for Rett syndrome and Fragile X syndrome.